Objective-The atheroprotective effects of estrogen are independent of circulating lipid levels. Whether estrogen regulates transcytosis of LDL (low-density lipoprotein) across the coronary endothelium is unknown. Approach and Results-Using total internal reflection fluorescence microscopy, we quantified transcytosis of LDL across human coronary artery endothelial cells from multiple donors. LDL transcytosis was significantly higher in cells from men compared with premenopausal women. Estrogen significantly attenuated LDL transcytosis by endothelial cells from male but not female donors; transcytosis of albumin was not affected. Estrogen caused downregulation of endothelial SR-BI (scavenger receptor class B type 1), and overexpression of SR-BI was sufficient to restore LDL transcytosis. Similarly, depletion of SR-BI by siRNA attenuated endothelial LDL transcytosis and prevented any further effect of estrogen. In contrast, treatment with estrogen had no effect on SR-BI expression by liver cells. Inhibition of estrogen receptors α and β had no effect on estrogen-mediated attenuation of LDL transcytosis. However, estrogen's effect on LDL transcytosis was blocked by depletion of the GPER (G-protein-coupled estrogen receptor). GPER was found to be enriched in endothelial cells compared with hepatocytes and is reported to signal via transactivation of the EGFR (epidermal growth factor receptor); inhibition of EGFR prevented the effect of estrogen on LDL transcytosis and SR-BI mRNA. Last, SR-BI expression was significantly higher in human coronary artery endothelial cells from male compared with premenopausal female donors. ; we also demonstrated that the high-affinity LDLR (LDL receptor) is not required. 15 However, while the cell biology of LDL transcytosis is now being investigated, little is known about how it is affected by cardiovascular risk factors.
A therosclerosis affects arteries in the second or third decades of life but manifests clinically only years later. The accumulation of lipids in the form of lipoproteins in the intimal layer of arteries is the first step in atherogenesis, 1 but the mechanisms of this accumulation remain poorly understood.
See accompanying editorial on page 2276
Conceptually, circulating lipoproteins could cross the endothelium into the vascular intima using gaps between endothelial cells (paracellular leak) or by passing through the cytoplasm of individual cells in the endothelial monolayer (transcytosis). 2 Early morphological studies used electron microscopy of rat arteries perfused with LDL (low-density lipoprotein); these showed that the LDL was internalized by cellular vesicles in the endothelium and directed to lysosomes or to the basal cell surface. 3 Importantly, the LDL was not observed to be crossing cell-cell junctions, implying that it had traversed the endothelial barrier by transcytosis. Although LDL has been postulated to exit the circulation at regions of mitotic or damaged endothelium, [4] [5] [6] the rate of endothelial mitosis is low (<0.05%), 7 and there is little in vivo evidence of endothelial apoptosis or denudation in early atherosclerosis in humans. 8 Last, LDL's size (≈20 nm 9 ) would prevent its paracellular passage in the presence of competent cell-cell junctions, 10 and autopsy studies have confirmed that the overlying endothelium is intact in early atherosclerotic lesions. 8 Thus the data suggest that LDL crosses the endothelium by transcytosis, [11] [12] [13] particularly early on in the disease. Transcytosis is an integrated form of vesicular traffic beginning with endocytosis at the luminal (apical) endothelial surface, traffic through the cell, and its exocytosis at the basal membrane.
14 Until recently, longstanding technical difficulties have largely precluded mechanistic investigations. In particular, it has been challenging to differentiate paracellular permeability from bona fide transcytosis in cultured cells, whereas electron microscopy (although elegant) is not well suited to elucidating mechanism. To overcome these barriers, we recently reported novel in vitro and ex vivo assays for LDL transcytosis, identifying 2 receptors (SR-BI [scavenger receptor class B type 1] and ALK1 [activin receptor-like kinase 1]) capable of transporting LDL through human coronary artery endothelial cells (HCAECs) 15, 16 ; we also demonstrated that the high-affinity LDLR (LDL receptor) is not required. 15 However, while the cell biology of LDL transcytosis is now being investigated, little is known about how it is affected by cardiovascular risk factors.
Of these, one of the most important is biological sex. It is well known that premenopausal women are protected from atherosclerosis [17] [18] [19] compared with age-matched men; conversely, the risk of atherosclerosis in women rises significantly after menopause. The biological mechanism of these epidemiological observations is unknown but is speculated to be related to the higher 17β-estradiol (estrogen) levels in premenopausal women versus men. 20 Whereas physiological levels of estrogen (≈0.1-1.5 nM 21 ) may induce a more favorable circulating lipid profile, this accounts for less than half of the protective effect. 19, 22 In fact, numerous animal studies have confirmed an atheroprotective effect of estrogen that is largely independent of circulating lipid levels. [23] [24] [25] [26] For instance, the administration of physiological concentrations of estrogen and progesterone to ovariectomized cynomolgus monkeys 27 decreased LDL accumulation in the arterial wall; this apparent decrease in vascular permeability to LDL occurred without a change in endothelial cell proliferation or leukocyte-endothelial adhesion. This and other studies suggest a direct atheroprotective effect of estrogen on the vessel wall, 28, 29 but to our knowledge the effect of estrogen on transcytosis of LDL has never been assessed.
Given the long latency of atherosclerosis and the presumptive role of LDL transcytosis in its initiation, we hypothesized that exposure to physiological levels of estrogen would attenuate LDL transcytosis by coronary artery endothelial cells. In this report, we describe the effects of estrogen on LDL transcytosis and the mechanisms involved.
Materials and Methods
The data that support the findings of this study are available from the corresponding author (W.L.L.) on reasonable request.
Cell Culture
Primary HCAECs were purchased from PromoCell (Heidelberg, Germany) and maintained in EGM-2 media with supplements (Lonza, Canada). Cells were from 7 donors, 3 men (aged 27, 48, and 58 years), 3 premenopausal women (aged 32, 32, and 40 years), and 1 postmenopausal woman (63 years old). For all experiments, HCAECs were used in passages 4 to 8. HepG2 cells were maintained in DMEM high-glucose media (glucose, 25 mmol/L) supplemented with fetal bovine serum (10% v/v), L-glutamine (2 mmol/L), sodium pyruvate (1 mmol/L), and HEPES (1 mmol/L; Sigma, Canada). All cells were incubated under humidified air containing 5% CO 2 at 37°C. Hep G2 cells were used up to passage 15. Real-time quantitative polymerase chain reaction (qPCR) analysis using SRY for detection of fetal Y chromosome 30 was conducted to confirm the biological sex, in addition to some limited demographic information available from the supplier.
Estrogen Treatment
17β-estradiol (estrogen, E2) was obtained from Sigma, Canada. Stock solutions in absolute ethanol were stored at −80°C. Appropriate dilutions in EGM-2 were then made and applied directly to cultures. Cells were incubated with estrogen for 48 hours, including being refreshed after 24 hours with fresh media with or without fresh estrogen. Control cultures received the ethanol vehicle (0.1%) alone. To eliminate confounding from estrogen in the media, in some experiments, cells were passaged in phenol red-free, serum-free medium containing 2% charcoal-stripped serum; charcoal stripping had no effect on the response of the endothelial cells to exogenous estrogen.
Chemical Inhibitors
In total internal reflection fluorescence (TIRF) microscopy experiments (see below), chemicals were maintained in the media for the membrane binding and live cell imaging portions of the experiments. All inhibitors were diluted in the recommended solvent and provided at established concentrations. In all experiments, chemical diluent was maintained at <0.2% final volume.
The specific estrogen receptor antagonist ICI 182 780 was from Abcam; the GPER (G-protein-coupled estrogen receptor) antagonist (G15) was from Cayman Chemical. A stock solution in 100% ethanol was diluted in EGM-2 before addition to cultures at the same time as estradiol. Cells were treated for 24 hours with ICI 182 780 or G15 at 1 μM. Tyrphostin AG-1478 (Sigma Canada) was diluted in absolute ethanol. Cells were incubated with Tyrphostin AG-1478 for 24 hours at 10 μM in EGM-2.
Transfection
For siRNA transfections, a master mix was made containing 150 μL Opti-MEM (ThermoFisher, Canada), 4 μL Lipofectamine RNAiMAX Reagent (ThermoFisher, Canada), and 32 nmol/L siRNA. HCAECs were transfected at 70% confluency in complete serum EGM-2, and media was changed 24 hours after transfection. All experiments on cells transfected with siRNA were performed 36 to 60 hours after transfection when the cells reached 100% confluency. Cell lysates were collected after the experiment to determine the degree of knockdown by immunoblot. In some experiments, total RNA was isolated from similar cells that were seeded on another plate and treated/transfected identically.
The SR-BI wild-type construct was a generous gift from Dr Dante Neculai. Transfection of plasmid DNA was performed on HCAECs that were 80% confluent using Lipofectamine-3000 (ThermoFisher, Canada). A mix containing 1 μg/mL plasmid DNA was added to Opti-MEM and then added to HCAECs in serum-free EGM-2. After 2 hours, media was changed to complete serum EGM-2. Experiments involving plasmid-transfected cells were performed 24 hours after transfection and at 100% confluency.
LDL Transcytosis Assay
TIRF microscopy uses an evanescent wave to illuminate just the proximal 100 nm or so of the cell; thus, we can selectively image the basal membrane of a live endothelial cell with minimal confounding from the overlying cytoplasm and apical surface. Essentially, confluent endothelial monolayers are exposed to a fluorophore-tagged 15 cells at 100% confluency were placed in a live cell imaging chamber and treated with 20 μg/mL DiI-LDL in cold HPMI media for 10 minutes at 4°C to allow apical membrane binding. In some experiments, cells were treated with 10 μg/mL Alexa 488 (A488)-conjugated albumin (Sigma, Canada). After membrane binding, cells are washed twice with cold PBS+ to remove unbound ligand, and room temperature HPMI is added. Cells are incubated on the live cell imaging stage at 37°C for 2 minutes before initial image acquisition. Confluent regions of the monolayer are selected by viewing the number of nuclei in the DAPI field of view after staining with NucBlue Live ReadyProbes Reagent (ThermoFisher, Canada) and TIRF microscopy of the basal membrane is performed to visualize exocytosis. For each coverslip, 10 to 15 videos of 150 frames (100-ms exposure) are captured. Image analysis is performed using a custom MATLAB single-particle-tracking algorithm originally written by Bryan Heit (London, Ontario) 15 and enhanced by S.G. and customized for our microscope.
Briefly, averaged extracellular background was subtracted from the images. The images are thresholded to obtain a binary image used as a mask. Vesicles are identified by applying a threshold 15% above the mean intensity, limiting detected vesicles to those between 60 and 200 nm in diameter 31, 32 and a circularity >0.2. Vesicles are tracked based on maximum probability, which is dependent on change in centroid particle and change of the peak intensity. Because exocytic vesicle fusion with the plasma membrane requires the vesicles to stably dock with the plasma membrane before releasing their cargo, we limit identification of transcytosis events to stationary and, therefore, potentially docked vesicles; this limits confounding by endocytic traffic. By quantification of the diffusivity (mean-squared displacement) of each vesicle, the Brownian motion of the vesicles is limited only to vesicles exhibiting subdiffusive behavior before exocytosis (α<1). Exocytosis events (ie, release of the fluorescent LDL from the vesicle) were then determined in this subdiffusive population by identifying vesicles that undergo a decrease in fluorescence signal 33 during the last 5 time points of their tracks equivalent to a drop of at least 3 SDs of vesicular intensity during the entire period the vesicle has been tracked. As an additional control, such vesicles are only counted if they do not reappear for 5 subsequent frames; this further reduces confounding by endocytic traffic.
TIRF imaging was performed at a penetration depth of 100 nm. As reported previously, unlike transwell assays, the TIRF assay for LDL transcytosis is not affected by paracellular gaps or the typically low transfection efficiency of primary cells. 15 In LDL transcytosis assays featuring plasmid-transfected cells, successfully transfected cells were first identified with the epifluorescent arc lamp.
LDL Uptake Assay
Cells were treated with serum-free media and placed in the incubator at 37°C for 30 minutes. Then, they were incubated with DiI-LDL (2 µg/ mL) at 37°C for 10 minutes and then washed twice with warm PBS. Cells were then fixed with 4% paraformaldehyde. Cells were then washed 3× with PBS and mounted on slides with DAPI-containing (1:5000) Dako Fluorescence Mounting Medium (Agilent, Canada).
Immunoblotting
Cell lysates were collected by lysing cells in SDS-containing lysis buffer with 2 mmol/L sodium orthovanadate (Sigma, Canada), 1 mmol/L PMSF (Sigma, Canada), 1X protease inhibitor cocktail (Roche, Canada), and 1X PhosSTOP (Sigma, Canada). Lysates were resolved on 10% polyacrylamide gel and transferred onto a nitrocellulose membrane and blocked for 1 hour in 5% BSA in TBS+0.1% Tween-20. Primary antibodies were diluted 1:1000 (1 µg/mL) in 0.5% BSA in TBST and incubated at 4°C overnight on a rocker. Primary antibodies were mouse anti-β-actin (sc-47778; Santa Cruz, CA), rabbit anti-SR-BI (NB400-104, Novus Bio, Canada), goat anti-LDLR (AF2418; R&D Systems, Minneapolis, MN), rabbit anti-α-actinin (No. 3134; Cell Signaling, Danvers, MA), rabbit anti-caveolin-1 (sc-894; Santa Cruz, CA), rabbit anti-GPER (NLS4271; Novus Bio, Canada), mouse anti-ERα (sc-787; Santa Cruz, CA) and mouse anti-ERβ (sc-390243; Santa Cruz, CA). After washing several times in TBST, membranes were incubated with HRP-conjugated secondary antibodies (1 μg/mL) for 1 hour at room temperature followed by detection by enhanced chemiluminescence (Clarity ECL; BioRad, Canada) and imaging on a ChemiDoc Imaging System (BioRad, Canada). Protein abundance was quantified by densitometry (ImageJ) after normalization to loading control.
Immunofluorescence
HCAECs were fixed/permeabilized in 100% iced cold methanol at −20°C for 10 minutes followed by washing 3× with PBS. Cells were blocked with 5% BSA in PBS for 30 minutes at room temperature followed by immunodetection with rabbit anti-caveolin-1 (sc-894; Santa Cruz, CA) diluted 1:100 (10 µg/mL) in PBS. After a 1-hour incubation at room temperature, cells were washed 3× in PBS and treated with species-specific, chromophore-conjugated secondary antibody diluted 1:1000 (Jackson ImmunoResearch Laboratories, West Grove, PA). Cells were then washed and mounted on slides with DAPI-containing (1:5000) Dako Fluorescence Mounting Medium (Agilent, Canada). Negative controls (no primary antibody) were included in all experiments. Slides were imaged by spinning disk confocal microscopy with settings kept constant between conditions.
RNA Isolation and qPCR
Total RNA was isolated from 100% confluent HCAECs seeded on 6-well plates. For measurement of siRNA-mediated knockdown efficiency by qPCR, RNA was isolated 48 hours after transfection. RNA isolation was performed with the Qiagen RNeasy RNA Isolation Kit according to manufacturer's instructions. cDNA synthesis was performed on 1 μg total RNA using Applied Biosystems HighCapacity cDNA Reverse-Transcription Kit. qPCR was performed on an Applied Biosystems ViiA 7 Real-Time PCR system: (1) 95°C for 3 minutes, (2) 95°C for 15 s, (3) 58°C for 30 s, (4) repeat from 2 an additional 39×, and (5) melt curve from 65°C to 95°C at 0.5°C increments. mRNA abundance is presented relative to 18S, which is a reference gene for our experiment. Primers for qPCR are listed in the Table, and the sequences were provided by PrimerBank. 34 
Statistics
Each experiment was performed at least 3×; results are expressed as mean and SEM. Statistical tests were performed using GraphPad Prism software, version 6.0 (La Jolla, CA); data were tested for normality and equal variance to confirm appropriateness of parametric tests. For experiments with 2 independent groups, P values were determined by paired, unpaired, and 1-sample t tests where appropriate. P<0.05 was deemed statistically significant. For experiments with >2 independent groups, P values were determined by 1-way ANOVA with significance set at P<0.05; post hoc testing was done using Tukey test.
Results

LDL Transcytosis Is Greater in Coronary Endothelial Cells From Men Than Premenopausal Women and Is Inhibited by Estrogen
Transcytosis rates of LDL were measured for primary HCAECs from 3 male (ages 27, 48, and 58 years) and 4 female donors (ages 32, 32, 40, and 63 years). Cells from the male donors exhibited a significantly higher rate of LDL transcytosis than the cells from the 3 young (and presumably premenopausal) female donors. Interestingly cells from a postmenopausal female donor exhibited a rate of LDL transcytosis similar to the male donors ( Figure 1A ). Cells were then exposed to increasing physiological concentrations of estrogen (E2) for 48 hours followed by measurement of LDL transcytosis. Estrogen induced a significant (>50%) reduction in LDL transcytosis by cells from all 3 male donors and from the postmenopausal donor that was dose dependent (Figure 1B through 1D ; Figure  I in the online-only Data Supplement); in contrast, estrogen had no effect on LDL transcytosis by coronary endothelial cells from 3 premenopausal female donors (Figure 1B 
Estrogen Induces Downregulation of SR-BI and LDLR but Not Caveolin-1 in Male Endothelial Cells
We sought to determine the mechanism by which estrogen reduced LDL transcytosis by male endothelial cells. Given the recent identification of SR-BI and ALK1 as receptors capable of LDL transcytosis, 15, 16 we hypothesized that estrogen might affect receptor levels or function. Physiological concentrations of estrogen reduced endothelial SR-BI mRNA and protein in a dose-dependent fashion (Figure 2A and 2B) , with similar effects on endothelial LDLR; we have previously shown that LDLR is not required for LDL transcytosis. 15 Conversely, mRNA for ALK1 message was not significantly affected by estrogen; lack of a good commercially available antibody to ALK1 precluded checking protein levels. Caveolae have been reported to regulate endothelial traffic of lipoproteins, as mice lacking caveolin-1 are protected against atherosclerosis. 35 However, estrogen had no effect on the levels or subcellular distribution of caveolin-1 in endothelial cells ( Figure 2C and 2D) .
SR-BI Is Required for the Effect of Estrogen on LDL Transcytosis by Male Endothelial Cells
To establish the functional significance of the changes in SR-BI expression, we transfected estrogen-treated cells with SR-BI or vector alone. As reported previously, 15 overexpression of SR-BI increased LDL transcytosis ( Figure 3A) . Estrogen exposure significantly reduced the internalization and transcytosis of LDL by vector-transfected coronary artery endothelial cells, but this was attenuated by overexpression of SR-BI ( Figure 3A through 3C ). More importantly, in cells depleted of SR-BI by siRNA, estrogen had no further effect to reduce LDL transcytosis ( Figure 3B ). Thus, SR-BI is required for the effect of estrogen. Together, this suggests that the effect of estrogen on endothelial LDL transcytosis is mediated in large part by alterations in SR-BI expression.
Estrogen Does Not Induce SR-BI Expression in the Liver and Induces LDL Internalization by Hepatocytes
The function of SR-BI is well characterized in the liver, where it mediates cholesterol uptake from circulating HDL (highdensity lipoprotein) thereby contributing to reverse cholesterol transport. 36 In contrast to the coronary endothelial cells, physiological levels of estrogen had no significant effect on SR-BI mRNA in HepG2 liver cells derived from a male donor ( Figure 4A) ; there was a trend toward increased SR-BI protein levels that did not achieve statistical significance ( Figure 4B ). However (and as reported by others 37 ), estrogen significantly increased levels of LDLR ( Figure 4A , right) with a resultant increase in LDL internalization by the hepatocytes (Figure 4C ). These data indicate that the effect of physiological concentrations of estrogen is tissue specific, leading to decreased LDL transcytosis via SR-BI by the coronary endothelium (eg, Figure 1 ) and increased hepatic LDL uptake likely via LDLR.
GPER Is Enriched in Endothelial Cells and Is Required for the Effect of Estrogen on LDL Transcytosis
Three receptors for estrogen exist: the nuclear ER (estrogen receptor)α and ERβ receptors and the more recently described GPER 38, 39 ; interestingly, the latter has been reported to be antiatherogenic. 40 Coronary endothelial cells exhibited an enrichment in GPER mRNA relative to the α and β receptors-a finding that was not observed in HepG2 cells ( Figure 5A ). ICI 182 780 (ICI) is a high-affinity estrogen antagonist to the α and β receptors that exhibits agonist activity to GPER. Treatment with ICI did not prevent estrogen's ability to attenuate LDL transcytosis, suggesting that estrogen is not acting through the α and β receptors (Figure 5B, left) . Instead, exposure to G15-a selective antagonist of GPER 41 -completely blocked the effect of estrogen on LDL transcytosis ( Figure 5B, right) . Furthermore, even partial knockdown of GPER by siRNA reversed the effect of estrogen on LDL transcytosis ( Figure 5C ) and endothelial SR-BI and LDLR levels ( Figure III in the online-only Data Supplement). GPER exerts its effect via transactivation of the EGFR (epidermal growth factor receptor), 38, 42 which can be selectively inhibited by Tyrphostin AG-1478. Treatment with Tyrphostin AG-1478 completely abrogated the effect of estrogen on LDL transcytosis ( Figure 5D ). Last, treatment with Tyrphostin AG-1478 prevented estrogen-induced downregulation of SR-BI mRNA levels ( Figure 5E ). Together, these data indicate that estrogen attenuates endothelial LDL transcytosis via its action on endothelial GPER.
SR-BI Expression Is Greater in Coronary Artery Endothelial Cells From Male Compared With Female Donors
Finally, we measured SR-BI levels in HCAECs from all 7 donors. Men displayed significantly higher levels of SR-BI in lysates compared with cells from premenopausal women ( Figure 6A ). Interestingly, overexpression of SR-BI in endothelial cells from a female donor partially restored the sensitivity of LDL transcytosis to exogenous estrogen ( Figure 6B ).
Discussion
It has been known for decades that premenopausal women exhibit a markedly lower rate of coronary artery disease compared with men and that this difference narrows rapidly after menopause. 19 The relative protection of premenopausal women has been attributed to beneficial effects of 17β-estradiol (estrogen); for example, estrogen replacement started <10 years after menopause has been associated with a decreased risk of coronary heart disease. 43 However, the mechanisms of estrogen's benefit still remain incompletely understood. In particular, abundant preclinical data and human data 19 indicate that the protective effect of estrogen cannot be completely explained by improvements in circulating lipid levels. Early studies suggested an effect of estrogen on the vessel wall 27, 29 : 1 report described how the administration of physiological concentrations of estrogen and progesterone to . GPER (G-protein-coupled estrogen receptor) is enriched in endothelial cells and is required for the effect of estrogen on LDL (low-density lipoprotein) transcytosis A, The GPER is enriched in male human coronary artery endothelial cell (HCAEC) but not in male HepG2. Levels of ER (estrogen receptor)α, ERβ, and GPER were measured by quantitative polymerase chain reaction (qPCR) and are normalized to 18S. P<0.05 by 1-way ANOVA; *P<0.05 by Tukey test. Data are mean and SEM from 3 independent experiments. B, The ERα-ERβ antagonist (ICI 182,780) had no effect on estrogen-mediated reduction in transcytosis, whereas the GPER-antagonist G15 inhibited the effect of estrogen. P<0.05 by 1-way ANOVA; ****P<0.0001 by Tukey test. Data are mean and SEM from 3 independent experiments. C, Depletion of GPER by siRNA prevents estrogen-mediated inhibition of transcytosis. Male HCAECs were treated with siRNA specific to GPER or nontargeting control (SCRM) before treatment with estrogen (1.0 nmol/L) for 48 h. Transcytosis of DiI-LDL was then measured. P<0.05 by 1-way ANOVA; ****P<0.0001 by Tukey test. Data are mean and SEM from 3 independent experiments. Representative Western blot and pooled quantification are shown at right. **P<0.01. D, Inhibition of EGFR (epidermal growth factor receptor) prevents estrogen-mediated (Continued ) ovariectomized cynomolgus monkeys 27 decreased LDL accumulation in the arterial wall without changing endothelial cell proliferation or leukocyte-endothelial adhesion. The implication was that permeability of the vessel to LDL was altered by estrogen, but transcytosis of LDL was not examined.
Despite its initial description decades ago, 3, 44 there is a marked paucity of literature of the transcytosis of LDL across the coronary endothelium. Recent technical advances are now enabling elucidation of its basic mechanisms, including the identification of contributing receptors and downstream signaling. 15, 16 However, little is known about how LDL transcytosis is affected from a pathological standpoint. For instance, although it has been reported that C-reactive protein can stimulate LDL transcytosis, 11 the effects of traditional cardiovascular risk factors, such as biological sex and diabetes mellitus, are unknown. For the first time, we report that physiologically relevant concentrations of estrogen greatly attenuate LDL transcytosis across primary human coronary artery endothelium.
Our data demonstrate that the effect of estrogen to inhibit LDL transcytosis is mediated in large part through downregulation of SR-BI-a scavenger receptor expressed on endothelial cells, as well as in the liver and on macrophages. We recently reported that it can mediate transcytosis of native (nonmodified) LDL across coronary artery endothelium. 15 Paradoxically, global deficiency of SR-BI causes increased levels of atherosclerosis, although the phenotype of these mice is likely dominated by SR-BI deficiency from the liver and macrophages. We speculate that endothelial SR-BI contributes to early atherosclerotic lesions and that this effect is masked in the SR-BI −/− mouse because of the receptor's antiatherogenic role in other tissues. [45] [46] [47] Here, we show that overexpression of SR-BI restores estrogen-inhibited LDL transcytosis to normal levels, whereas knockdown of SR-BI prevents any further effect of estrogen. Despite the downregulation by estrogen of the high-affinity LDLR in endothelial cells, LDLR is not required for LDL transcytosis by coronary endothelial cells, 15 in contrast to its role in the cerebral circulation. 48 Furthermore, we observed no effect of estrogen on levels of ALK1-another receptor recently reported to mediate LDL transcytosis. 16 Estrogen also had no effect on the levels or intracellular distribution of caveolin-1-the major structural protein in caveolae, which has been reported to regulate lipoprotein transport. 35 The consequence of estrogen administration was tissue specific, leading to downregulation of SR-BI and LDLR in coronary endothelial cells but not in hepatocytes. The effect was also specific for transcytosis of LDL because estrogen did not alter the endothelial transcytosis of albumin.
The nuclear receptor ERα is thought to be the major target for estrogen in mediating protection from atherosclerosis. 23, 24 For instance, Apoe −/− mice develop accelerated atherosclerosis that is markedly reduced in ovariectomized mice given exogenous estrogen-this beneficial effect is significantly attenuated in mice deficient in ERα. Nonetheless, estrogen administration reduces atherosclerotic lesion size and complexity even in the ERα-deficient animals. 24 Furthermore, in a mouse model of early atherosclerosis, ovariectomized mice that received estrogen demonstrated a significant reduction in fatty streaks even in the absence of ERα. 25 These data suggest that another estrogen receptor may be contributing to the beneficial effects of estrogen.
Using primary HCAECs, we now show that estrogen downregulates SR-BI through GPER-a transmembrane estrogen receptor 38 that is distinct from ERα and ERβ. On binding to estrogen, GPER acts via transactivation of the EGFR and has been reported to be antiatherogenic via effects on endothelial NO. 40 To our knowledge, the link between GPER and endothelial SR-BI is novel: by contrast, in breast carcinoma cells, estrogen has been reported to induce SR-BI via both ERα and ERβ and SREPB1a (sterol regulatory element-binding protein 1). 49 Instead, our data confirm that GPER is enriched relative to these receptors in endothelial cells; we also show using both molecular and pharmacological approaches that it is required for the effect of estrogen on LDL transcytosis via a pathway requiring EGFR signaling. Although inhibition of ERα and ERβ did not affect the estrogen-mediated reduction in LDL transcytosis, knockdown of GPER and inhibition of EGFR both did; similarly, knockdown of GPER or inhibition of EGFR prevented the downregulation of SR-BI induced by estrogen. Although to our knowledge, this is the first description of a proposed link between GPER and SR-BI, it is noteworthy that some elements of the reverse relationship have been suggested; specifically, it has been shown that HDL-the canonical ligand for SR-BI 50 -can decrease EGFR activation. 51 Curiously, the effect of estrogen to decrease LDL transcytosis was observed in coronary artery endothelial cells from 3 male donors but not in cells derived from 3 young female donors. This is despite serial passaging of the female-derived cells in estrogen-depleted media by charcoal stripping (data not shown); interestingly, estrogen did decrease LDL transcytosis by cells from a postmenopausal women. In addition, SR-BI levels were significantly lower in the cells from the premenopausal women compared with the male donors. Limited availability, high cost, and lack of detailed clinical information on cells from distinct donors posed a technical challenge and limited our ability to make generalizations: we could only test cells from 7 donors and were unable to obtain additional cells from postmenopausal female donors. Intriguingly, overexpression of SR-BI in the female cells partially restored estrogen's ability to inhibit LDL transcytosis, whereas GPER levels were inducible by estrogen in the male but not the female cells ( Figure IV in the online-only Data Supplement). These data suggest that the GPER-SR-BI axis is relatively unresponsive or suppressed in the female endothelial cells. However, future studies will be necessary to determine whether these findings are broadly generalizable and to completely elucidate the underlying mechanism.
Interestingly, we observed no difference in SR-BI levels in the aortic endothelium of age-matched male and female mice (data not shown). However, unlike humans, female mice are generally reported to exhibit higher rates of atherosclerosis than males. 52 The dominant lipoprotein in mice is VLDL (very-low-density lipoprotein), not LDL, and mouse models of atherosclerosis emphasize the late stages of the disease. In contrast, we think that the use of primary HCAECs from numerous donors constitutes a strength of our work.
The markedly lower rates of atherosclerosis in premenopausal women compared with men have been noted for decades, yet remain incompletely understood. 53 To our knowledge, this is the first report showing that physiological concentrations of estrogen significantly reduce LDL transcytosis and that this occurs via GPER-mediated signaling, leading to decreased endothelial SR-BI expression. In combination with previously described effects of estrogen, such as on circulating lipid levels and LDL oxidation, 54 our findings suggest an additional mechanism by which premenopausal women are protected from atherosclerosis compared with men. 
